Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.

Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.

Show other versions (1)

As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of rituximab (Roche Products) to submit evidence of the clinical and cost effectiveness of rituximab in combination with corticosteroids for treatment of an...

Full description

Bibliographic Details
Main Authors:	Latimer, N, Carroll, C, Wong, R, Tappenden, P, Venning, M, Luqmani, R
Format:	Journal article
Language:	English
Published:	2014

Similar Items

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
by: Latimer, N, et al.
Published: (2014)

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
by: Guerry, M, et al.
Published: (2012)

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
by: Flossmann, O, et al.
Published: (2006)

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
by: Robson, J, et al.
Published: (2017)

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.
by: Basu, N, et al.
Published: (2014)

Anti-neutrophil cytoplasmic antibody associated vasculitis following rituximab: Outcomes of 50 patients in a tertiary single centre
by: Fahidah Alenzi, et al.
Published: (2023-09-01)

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis
by: Pearce, F, et al.
Published: (2017)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation
by: Valentina Binda, et al.
Published: (2021-12-01)

A disease-specific patient-reported outcome for anti-neutrophil cytoplasmic antibody–associated vasculitis: scale structure and measurement properties of the anti-neutrophil cytoplasmic antibody-associated vasculitis patient-reported outcome measure
by: Robson, J, et al.
Published: (2017)

A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis
by: Marta Casal Moura, et al.
Published: (2022-11-01)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
by: Hellmich, B, et al.
Published: (2007)

Recent advances in the diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
by: Si-wei Tang, et al.
Published: (2024-03-01)

Oral Microbiota Profile in Patients with Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis
by: Anders Esberg, et al.
Published: (2022-08-01)

Late Onset of Rivaroxaban-Associated Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis
by: Muskan Agarwal MD, et al.
Published: (2023-10-01)

A case of Sjögren syndrome and anti-neutrophil cytoplasmic antibody-associated vasculitis
by: K. Kaynar, et al.
Published: (2023-07-01)

Clinical significance of HEp-2 cell cytoplasmic patterns in anti-neutrophil cytoplasmic antibody associated vasculitis
by: Naidan Zhang, MS, et al.
Published: (2022-06-01)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
by: Luqmani, R, et al.
Published: (2017)

Dual diagnosis of histiocytoid Sweet syndrome and anti-neutrophil cytoplasmic antibody-associated vasculitis
by: Hildur Jónsdóttir, MD, et al.
Published: (2022-05-01)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
by: Mukhtyar, C, et al.
Published: (2006)

CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis
by: Sarvestani Ghafar, et al.
Published: (2008-07-01)

Pulmonary involvement in Anti‐Neutrophil Cytoplasmic Antibody Associated Vasculitis: A single centre case series
by: Peter T. Bell, et al.
Published: (2022-11-01)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
by: Merkel, P, et al.
Published: (2009)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
by: McLaren, J, et al.
Published: (2001)

Animal models for anti‐neutrophil cytoplasmic antibody‐associated vasculitis: Are current models good enough?
by: Fei Huang, et al.
Published: (2023-10-01)

Measurement of superoxide dismutase: clinical usefulness for patients with anti-neutrophil cytoplasmic antibody-associated vasculitis
by: Zhihuan Zhang, et al.
Published: (2023-06-01)

Plasma Exchange in the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Analysis
by: Ebru Gök Oğuz, et al.
Published: (2022-10-01)

Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
by: Robson, J, et al.
Published: (2016)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
by: Mukhtyar, C, et al.
Published: (2008)

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
by: Robson, J, et al.
Published: (2014)

Present and future management of anti-neutrophil cytoplasmic antibody associated vasculitis: how therapy changed the prognosis
by: Massimo L’Andolina, et al.
Published: (2013-03-01)

Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future
by: Menglu Pan, et al.
Published: (2023-04-01)

Determinants of patient and physician global assessments of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis
by: Marius Rohde, et al.
Published: (2023-02-01)

Cardiovascular Outcomes Are Worse In Microscopic Polyangiitis Compared To Granulomatosis With Polyangiitis: Data From An Inception Cohort Of Patients With Anti-Neutrophil Cytoplasm Antibody Associated Systemic Vasculitis
by: Mistry, A, et al.
Published: (2013)

Cytoplasmic Pattern Anti-neutrophil Cytoplasmic Antibody (cANCA)-positive Cutaneous Leukocytoclastic Vasculitis Induced by Propylthiouracil: A Case Report
by: Gulsah Elbuken, et al.
Published: (2016-06-01)

The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting.
by: McLaren, J, et al.
Published: (2001)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
by: Luqmani, R, et al.
Published: (2017)

A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.
by: McLaren, J, et al.
Published: (2000)

Association between follistatin-related protein 1 and the functional status of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis
by: Taejun Yoon, et al.
Published: (2021-05-01)

Herpes Zoster Precipitating First Attack of Neuromyelitis Optica along with Perinuclear Anti-Neutrophilic Cytoplasmic Antibody Positive Vasculitis
by: Rajesh Verma, et al.
Published: (2022-01-01)

Early outcomes in children with antineutrophil cytoplasmic antibody-associated vasculitis
by: Morishita, K, et al.
Published: (2017)